<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03903185</url>
  </required_header>
  <id_info>
    <org_study_id>CL 3062</org_study_id>
    <nct_id>NCT03903185</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy</brief_title>
  <official_title>Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, controlled, open-label, pharmacokinetic study. This study aims at
      studying the PK of ledipasvir, sofosbuvir, and GS-331007 metabolite in HCV infected children
      with hematological malignancy.

      In this study, patients in both treatment groups will receive 12 weeks of treatment with a
      ﬁxed-dose combination tablet containing 45 mg of ledipasvir and 200 mg of sofosbuvir
      (LDV/SOF) orally, once daily with food.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, patients in both treatment groups will receive 12 weeks of treatment with a
      ﬁxed-dose combination tablet containing 45 mg of ledipasvir and 200 mg of sofosbuvir
      (LDV/SOF) orally, once daily with food, as prescribed by the attending physician.

      Twelve eligible HCV-infected patients with hematological malignancy and 12 matching HCV
      control patients without haematological malignancy or co-morbidities will be enrolled in the
      study.

      At baseline, careful history of the recruited patients including demographic characteristics
      (age, height, weight, and gender), comorbidities, medication history, familial history,
      social history, blood transfusion history, time on maintenance chemotherapy, and baseline
      laboratory tests will be documented. The baseline laboratory tests will include renal
      function tests (serum creatinine), liver function tests (bilirubin, albumin, AST, and ALT),
      international normalized ratio (INR), alpha fetoprotein (AFP), complete blood count (CBC),
      degree of liver fibrosis by Fibroscan, and viral load by PCR.

      Followup will be done for all participants at baseline, after 12 weeks of treatment, and
      after 12 weeks from the end of treatment. A Forth visit will be done after 10 days of
      treatment for the evaluation of the steady state PK parameters of LDV\SOF in those patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of the pharmacokinetics of LDV\SOF</measure>
    <time_frame>Blood samples will be collected after 10 days of treatment</time_frame>
    <description>After 10 days of treatment, the steady state for LDV/SOF will be reached. Serial blood samples (2 mL/sample) will be collected at this time for the determination of LDV/SOF and GS-331007 concentrations from patients using an eight-point plasma schedule.
Blood sampling schedule will be as follows (Predose, 0.5,1, 2, 3, 4, 8, and 12h post dose; with predose also serving as t = 24).
Any deviations from nominal sampling times will be accurately recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of the number of participants with sustained virological response (SVR12), 12 weeks after discontinuation of therapy with ledipasvir-sofosbuvir (LDV-SOF).</measure>
    <time_frame>12 weeks after discontinuation of therapy with ledipasvir-sofosbuvir (LDV\SOF)</time_frame>
    <description>Number of Participants with sustained virological response at 12 Weeks after end of study drug treatment (SVR12) will be recorded.
Participant will be considered to have achieved SVR12 if HCV RNA is less than the lower limit of quantification of &lt;15 IU/ml) at 12 weeks after the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>HCV-infected patients with hematological malignancy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HCV-infected patients with hematological malignancy on maintenance chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control HCV-infected patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control HCV-infected patients without haematological malignancy or co-morbidities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ledipasvir / Sofosbuvir Oral Product</intervention_name>
    <description>45 mg of ledipasvir and 200 mg of sofosbuvir orally, once daily with food</description>
    <arm_group_label>Control HCV-infected patients</arm_group_label>
    <arm_group_label>HCV-infected patients with hematological malignancy</arm_group_label>
    <other_name>LDV\SOF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children (6 to &lt; 12 years of age and/or weighing 17.5 to &lt; 35 Kg).

          -  Chronic HCV genotype 4 infection for at least 6 months without cirrhosis (confirmed by
             Fibroscan).

          -  Naïve patients to previous anti-HCV treatment.

          -  Diagnosed with hematological malignancy and on maintenance chemotherapy.

        Exclusion Criteria:

          -  Known hypersensitivity to any of the study medications.

          -  Ongoing treatment with any interacting medications like carbamazepine, fosphenytoin,
             phenytoin, oxcarbazepine, phenobarbital, and rifampin.

          -  History of any comorbid illness that may interfere with the pharmacokinetics of the
             study drugs or prohibit the compliance with the study protocol such as;

               1. Decompensated liver disease as shown by the presence of ascites, encephalopathy,
                  or a history of variceal hemorrhage.

               2. The ongoing treatment of other types of cancer or blood disorders.

               3. Co-infection with human immunodeficiency virus (HIV), or hepatitis B virus.

               4. Renal dysfunction.

               5. Active infection that is currently producing symptoms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manal H Elsayed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manal H ElSayed, MD</last_name>
    <phone>01227461120</phone>
    <email>manalhelsayed@yahoo.co.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fatma S Ebeid, MD</last_name>
    <phone>01095569596</phone>
    <email>dr.fatma_ebeid@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pediatric Department, Faculty of Medicine, Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <zip>11556</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manal H El-Sayed, MD</last_name>
      <phone>01227461120</phone>
      <email>manalhelsayed@yahoo.co.uk</email>
    </contact>
    <contact_backup>
      <last_name>Fatma S Ebeid, MD</last_name>
      <phone>01095569596</phone>
      <email>dr.fatma_ebeid@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Manal H ElSayed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aya M Abdel Magid, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maggie M Abbassi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samar F Farid, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fatma S Ebeid, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammed Hassany, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Manal Hamdy El-Sayed</investigator_full_name>
    <investigator_title>Professor of Pediatrics and Director of the Clinical Research Center</investigator_title>
  </responsible_party>
  <keyword>Hepatitis C virus</keyword>
  <keyword>Pharmacokinetic Modeling</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Ledipasvir</keyword>
  <keyword>Sofosbuvir</keyword>
  <keyword>Antiviral Drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

